EP420: Paying Cash for Generic Drugs—Some Finer Points That Had Totally Gone Over My Head, With Ge Bai, PhD, CPA

Cash-pay generic drugs sound like a fringe idea until you look at the numbers: for patients in their deductible phase, paying cash beats the price their PBM "negotiated" 79% of the time. Following on directly from last week's conversation about the financialization of health benefits (EP419), Stacey Richter talks with Ge Bai, PhD, CPA — a professor of accounting at Johns Hopkins Carey Business School who studies nothing but healthcare dollars — about two studies that reframe how cheap generic drugs actually get priced, and about who really profits when a patient runs a $3 prescription through insurance instead of just paying for it.

WHAT YOU'LL LEARN

✅ Why generic drugs are already cheap thanks to manufacturing competition — and why that undercuts the whole rationale for a PBM's market power to "negotiate" a better price

✅ The study showing that for patients in their deductible phase, paying cash for a generic beats the PBM-negotiated price 79% of the time

✅ Why PBMs, not manufacturers, pharmacies, or wholesalers, capture the largest margin in a typical generic drug transaction — by about 10 percentage points

✅ Why insurance and PBMs exist to pool risk, and why the administrative cost of spreading a $3 drug expense across an entire risk pool can end up costing more than the drug itself

✅ Why Ge Bai is skeptical that HSAs solve the affordability problem, given how much financial literacy they demand from patients who already can't reliably explain what a deductible is

WHY THIS MATTERS

Insurance and PBMs are built to pool risk for expensive, unpredictable events — not to add an administrative toll booth in front of a $3 prescription that's already competitively priced. When the intermediary designed to lower costs ends up capturing the largest margin in the transaction, the system isn't protecting patients from unaffordable care; it's manufacturing unaffordability out of something that was already cheap. Ge Bai's research suggests the bar for doing better by patients on generics is lower than most people assume — it just requires asking who actually benefits from routing a cheap drug through an expensive process.

MENTIONED IN THIS EPISODE

EP344 with Steven Quimby, MD: Apple Podcasts | Spotify | Other Apps

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

📺 Subscribe to our YouTube channel

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

06:13 What is the background on generic drugs that is need-to-know?

06:39 EP344 with Steven Quimby, MD.

07:04 Do we have affordability for generic drugs?

15:40 What's the policy failure around generic drugs?

18:34 Why is there a huge health equity issue?

20:13 How do PBMs have both a monopoly and a monopsony?

21:59 What should be the goal for cheap generics?

23:36 "Whenever we have no competition, we'll see high price."

26:00 What's the best approach to addressing operational challenges behind generic drug costs?

28:42 How do we solve generic drug costs on the back end?

31:15 "Healthcare insurance is not the same as health."

36:07 "It's time for us to reflect and think whether there is a better way to try."